CA Cancer J Clin 2010 May-Jun
Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology.
Related Questions
More specifically, which cardiac risk factors do you look for? Diabetes? Previous MI? Dyslipidemia? Peripheral vascular disease? CHF?
New answer by Radiation Oncologist at University of Chicago (May 9, 2014)
For men with intermediate risk disease, the jury’s still out pending RTOG 0815 as to which men will benefit most from ADT. Retrospective data suggest that a ...